Author: Katrina Hui

Vancomycin dose optimisation in patients receiving high-flux haemodialysis

Katrina Hui (1), Kashyap Patel (2), David CM Kong (1), Carl M Kirkpatrick (1) and KAOS group (3,4)
1. Centre for Medicine Use and Safety, Monash University, Melbourne; 2. Certara L.P, New Jersey; 3. Royal Melbourne Hospital, Melbourne; 4. Western Hospital, Melbourne

Background: Vancomycin is the most commonly prescribed intravenous (IV) antibiotic in the high-flux haemodialysis (HFHD) setting. The aim of this study was to develop a population pharmacokinetic (PK) model for vancomycin in HFHD to examine the probability of target attainment (PTA) of several dosing regimens of vancomycin to optimise dosing. Methods: Data were collected retrospectively […]

Read More

Impact of high-flux haemodialysis on the probability of target attainment for amoxycillin/clavulanic acid combination therapy

Katrina Hui(1), Kashyap Patel(1), David Kong (1), Michelle Nalder (2), Eugenie Pedagogos (3), Craig Nelson (4,5), Kirsty Buising (6) and Carl M Kirkpatrick (1)
1. Centre for Medicine Use and Safety, Monash University, 2. Department of Pharmacy, Royal Melbourne Hospital, 3. Department of Nephrology, Royal Melbourne Hospital, 4. Department of Nephrology, Western Health, 5. North West Academic Centre, University of Melbourne, 6. Victorian Infectious Diseases Service, Royal Melbourne Hospital

Introduction: High-flux dialysers are widely used in patients receiving haemodialysis due to increased permeability, solute flow and positive outcomes for patients. The clearances of small molecules, including amoxycillin (Amox)/clavulanic acid (Clav), are likely to increase during high-flux haemodialysis (HFHD). This will result in lower exposure and importantly, reduced efficacy. Objectives: This simulation study evaluates the […]

Read More